Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Wells Fargo & Company MN

Wells Fargo & Company MN boosted its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 44.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 57,004 shares of the company’s stock after purchasing an additional 17,451 shares during the period. Wells Fargo & Company MN owned approximately 0.15% of Tarsus Pharmaceuticals worth $3,156,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in TARS. Thoroughbred Financial Services LLC acquired a new position in Tarsus Pharmaceuticals in the 4th quarter worth $262,000. Geode Capital Management LLC increased its position in shares of Tarsus Pharmaceuticals by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 838,804 shares of the company’s stock worth $46,456,000 after acquiring an additional 3,014 shares during the last quarter. AIGH Capital Management LLC lifted its stake in shares of Tarsus Pharmaceuticals by 9.9% in the fourth quarter. AIGH Capital Management LLC now owns 224,713 shares of the company’s stock worth $12,442,000 after acquiring an additional 20,300 shares in the last quarter. Pictet Asset Management Holding SA purchased a new position in Tarsus Pharmaceuticals in the fourth quarter valued at about $284,000. Finally, Blair William & Co. IL acquired a new stake in Tarsus Pharmaceuticals during the 4th quarter valued at approximately $1,508,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Trading Up 1.1 %

NASDAQ:TARS opened at $50.00 on Thursday. The stock has a market cap of $1.92 billion, a price-to-earnings ratio of -13.12 and a beta of 0.94. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals, Inc. has a 1 year low of $20.08 and a 1 year high of $57.28. The business has a fifty day moving average of $47.62 and a 200-day moving average of $48.02.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The firm had revenue of $66.41 million during the quarter, compared to analyst estimates of $58.80 million. Equities analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and set a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. Barclays decreased their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Jefferies Financial Group upped their price objective on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. Guggenheim reiterated a “buy” rating and issued a $78.00 target price (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Finally, Oppenheimer upped their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $63.67.

Insider Buying and Selling at Tarsus Pharmaceuticals

In related news, CEO Bobak R. Azamian sold 7,131 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $330,093.99. Following the sale, the chief executive officer now directly owns 70,720 shares in the company, valued at $3,273,628.80. The trade was a 9.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Dianne C. Whitfield sold 2,315 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $107,161.35. Following the sale, the insider now owns 50,751 shares of the company’s stock, valued at $2,349,263.79. The trade was a 4.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 32,542 shares of company stock valued at $1,581,173. 8.25% of the stock is owned by insiders.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.